1. Home
  2. PWR vs VRTX Comparison

PWR vs VRTX Comparison

Compare PWR & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PWR

Quanta Services Inc.

HOLD

Current Price

$668.31

Market Cap

106.2B

Sector

Industrials

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$528.04

Market Cap

124.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PWR
VRTX
Founded
1997
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
EDP Services
Sector
Industrials
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
106.2B
124.7B
IPO Year
1997
2006

Fundamental Metrics

Financial Performance
Metric
PWR
VRTX
Price
$668.31
$528.04
Analyst Decision
Buy
Buy
Analyst Count
21
29
Target Price
$564.40
$539.69
AVG Volume (30 Days)
1.2M
1.5M
Earning Date
04-30-2026
05-04-2026
Dividend Yield
0.07%
N/A
EPS Growth
12.77
836.54
EPS
1.45
4.02
Revenue
$28,479,697,000.00
$2,488,652,000.00
Revenue This Year
$18.56
$10.79
Revenue Next Year
$12.72
$10.47
P/E Ratio
$460.74
$131.43
Revenue Growth
20.31
46.20
52 Week Low
$363.01
$362.50
52 Week High
$788.75
$529.14

Technical Indicators

Market Signals
Indicator
PWR
VRTX
Relative Strength Index (RSI) 42.77 81.04
Support Level $642.11 $422.12
Resistance Level $742.73 N/A
Average True Range (ATR) 26.84 13.62
MACD -3.54 6.11
Stochastic Oscillator 19.60 98.77

Price Performance

Historical Comparison
PWR
VRTX

About PWR Quanta Services Inc.

Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two segments: electric and underground utility and infrastructure.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: